Please login to the form below

Yescarta

This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

Gilead also had new, two-year data to share on its already-marketed CAR-T Yescarta (axicabtagene ciloleucel) in r/r B-cell lymphoma that showed a sustained treatment effect, answering ... After median follow-up of 27.1 months and a minimum of 24 months

Latest news

Digital tech from Autolus and Oxford BioMedica to speed advanced therapies

The first ever CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta gained European approval in August, and NHS England has fast-tracked their uptake on the health service, aiming to
Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Kite was sold on to Gilead Sciences, along with FDA-approved CAR-T therapy Yescarta, one of the first two of the groundbreaking cell therapies to reach the market, just behind
Gilead strikes deal with NHS England on CAR-T Yescarta

NHS England claims adult leukaemia access is first in Europe. NHS England has agreed a market access deal with Gilead for its groundbreaking CAR-T therapy Yescarta, and is claiming it ... Not far behind Yescarta in the NICE process in DLBCL is
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

This leaves the appraisal of Gilead’s Yescarta just a month ahead of its rival, with the second appraisal meeting on it scheduled for 27 September. ... This adds to Gilead’s advantage in clinical trial data, where its Yescarta looks to have
Gilead optimistic about Yescarta deal in UK

Of the patients treated with a single infusion of Yescarta, 72% responded to therapy (overall response rate). ... Kymriah earned $16m in the second quarter, while Yescarta has reached $68m, ahead of consensus forecasts.

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

New models of NHS care – new models of pharma response?

Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

therapies, such as CAR-Ts Kymriah and Yescarta.
The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June ... Kymriah and Yescarta might
Bluebird Bio: on the cusp of a gene therapy revolution

drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... rival Yescarta also providing price guides once they gain approval, also likely by the end of this year.
Health on instalment

Cancer drugs Kymriah and Yescarta go for $475, 000 and $375, 000 respectively.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

Training the next generation of biotech leaders

In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager- Healthcare Advertising: Negotiable

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Manager: Negotiable

Principal Health Economist - North-West: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Medical (Scientific) Director: £120, 000 benefits

Associate Medical Director: Excellent PTO, bonus and 401k package

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Account Director – Healthcare Marketing – Berks: Salary TBC

Experienced Medical Writers: Competitive Salary and Benefits

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Healthcare Communications Account Directors x 2: Salary TBC

Editorial Manager - MedComms: DOE

Business Development Director – Health Education: excellent commission

Business Director: Competitive Salary Offered

Associate Director: £75, 000-90, 000

Medical Writer: Salary TBC

Senior Editorial Assistant – Greater Manchester: DOE

Account Executive/ Senior Account Executive: competitive Salary Offfered

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Senior Account Manager: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Is China ready for a pharmaceutical gold rush?: Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...